[Clinical utility of serous tumoural markers].
作者信息
Martín Suárez A, Alonso Díaz L, Ordiz Alvarez I, Vázquez J, Vizoso Piñeiro F
机构信息
Residente de Medicina Familiar y Comunitaria. Hospital de Jove. Gijón. Asturias. España.
出版信息
Aten Primaria. 2003;32(4):227-39. doi: 10.1016/s0212-6567(03)79257-9.
Abstract
摘要
相似文献
1
[Clinical utility of serous tumoural markers].[浆液性肿瘤标志物的临床应用]
Aten Primaria. 2003;32(4):227-39. doi: 10.1016/s0212-6567(03)79257-9.
2
Two cases of breast carcinoma with osteoclastic giant cells: are the osteoclastic giant cells pro-tumoural differentiation of macrophages?两例伴有破骨细胞样巨细胞的乳腺癌：破骨细胞样巨细胞是巨噬细胞的促肿瘤分化吗？
Diagn Pathol. 2010 Aug 23;5:55. doi: 10.1186/1746-1596-5-55.
3
Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.浆液性和黏液性卵巢交界性肿瘤中肿瘤标志物与临床病理特征的比较
Eur J Gynaecol Oncol. 2012;33(1):25-30.
4
The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.TP53 和 CDKN2A 对鉴别卵巢高级别浆液性癌和低级别浆液性卵巢肿瘤的诊断效用。
Mod Pathol. 2013 Sep;26(9):1255-63. doi: 10.1038/modpathol.2013.55. Epub 2013 Apr 5.
5
The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.免疫组织化学和电子显微镜在鉴别腹膜间皮瘤和浆液性癌中的诊断效用：一项比较研究
Mod Pathol. 2006 Jan;19(1):34-48. doi: 10.1038/modpathol.3800471.
6
Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.探讨预测性生物标志物在浆液性卵巢癌中的临床影响。
Curr Drug Targets. 2020;21(10):974-995. doi: 10.2174/1389450120666191016143836.
7
Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.浆液性交界性卵巢肿瘤的分子亚型表现出良性肿瘤和恶性肿瘤相关特征的明显表达模式。
Mod Pathol. 2014 Mar;27(3):433-42. doi: 10.1038/modpathol.2013.130. Epub 2013 Aug 16.
8
Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.免疫组织化学在鉴别上皮性腹膜间皮瘤与腹膜及卵巢浆液性癌中的作用。
Am J Surg Pathol. 1998 Oct;22(10):1203-14. doi: 10.1097/00000478-199810000-00005.
9
Cyst fluid NB/70K concentration and leukocyte esterase: two new markers for differentiating pancreatic serous tumors from pseudocysts.囊液NB/70K浓度和白细胞酯酶：区分胰腺浆液性肿瘤与假性囊肿的两个新标志物。
Pancreas. 1995 May;10(4):342-6. doi: 10.1097/00006676-199505000-00004.
10
BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.BAP1 和 Claudin-4 可可靠地区分交界性和低级别浆液性卵巢肿瘤与腹膜间皮瘤，而 MTAP 则不行。
Int J Gynecol Pathol. 2023 Mar 1;42(2):159-166. doi: 10.1097/PGP.0000000000000877. Epub 2022 May 20.
引用本文的文献
1
[Clinical use of serum tumour markers].[血清肿瘤标志物的临床应用]
Aten Primaria. 2004 Mar 31;33(5):290. doi: 10.1016/s0212-6567(04)79420-2.
本文引用的文献
1
AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND.一种存在于前列腺转移癌患者血清中的“酸性”磷酸酶。
J Clin Invest. 1938 Jul;17(4):473-8. doi: 10.1172/JCI100974.
2
DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.通过免疫耐受和吸收技术证明人类结肠癌中的肿瘤特异性抗原
J Exp Med. 1965 Mar 1;121(3):439-62. doi: 10.1084/jem.121.3.439.
3
Serum tumor markers: past, state of the art, and future.血清肿瘤标志物：过去、现状与未来。
Int J Biol Markers. 2001 Apr-Jun;16(2):73-86.
4
[Preoperative serum levels of the carcinoembryonic antigen (CEA) and prognosis in colorectal cancer].[术前血清癌胚抗原（CEA）水平与结直肠癌预后]
Rev Esp Med Nucl. 2001 Aug;20(5):358-64. doi: 10.1016/s0212-6982(01)71974-x.
5
[Tumoral secretion markers: something more than clinical indicators].[肿瘤分泌标志物：不仅仅是临床指标]
Rev Esp Med Nucl. 2001 Aug;20(5):349-52. doi: 10.1016/s0212-6982(01)71972-6.
6
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.2000年乳腺癌和结直肠癌肿瘤标志物使用建议更新：美国临床肿瘤学会临床实践指南
J Clin Oncol. 2001 Mar 15;19(6):1865-78. doi: 10.1200/JCO.2001.19.6.1865.
7
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis.金属蛋白酶：在乳腺癌发生、侵袭和转移中的作用
Breast Cancer Res. 2000;2(4):252-7. doi: 10.1186/bcr65. Epub 2000 Jun 7.
8
The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer.肿瘤标志物CA 15-3在乳腺癌患者初诊时的预后价值。
Int J Biol Markers. 2000 Oct-Dec;15(4):340-2. doi: 10.1177/172460080001500412.
9
2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines.美国临床肿瘤学会结直肠癌监测指南2000年更新版
J Clin Oncol. 2000 Oct 15;18(20):3586-8. doi: 10.1200/JCO.2000.18.20.3586.
10
Tumour marker measurements in the diagnosis and monitoring of breast cancer.肿瘤标志物检测在乳腺癌诊断和监测中的应用
Cancer Treat Rev. 2000 Apr;26(2):91-102. doi: 10.1053/ctrv.1999.0151.
Zotero 插件